Year: 2015
Type: article
Abstract: Patients with chronic obstructive pulmonary disease (COPD) generally have lower fat-free mass (a surrogate marker of skeletal muscle mass) compared with their healthy peers [1, 2], and this is associated with decreased functional capacity [3], the presence of other comorbidities ( e.g. osteoporosis and renal impairment) [4] and increased mortality risk [5]. To date, longitudinal observational studies have shown no difference in the mean decline in fat-free mass over time between COPD patients and non-COPD control subjects [6, 7]. However, it remains unknown whether and to what extent a subgroup of COPD patients suffer continuous loss of fat-free mass. We hypothesised that COPD patients have 1) a higher prevalence of continuous fat-free mass decline, and 2) that this subgroup has a steeper decline of fat-free mass compared with a non-COPD control group with a continuous fat-free mass decline. We tested this hypothesis in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, which had a 3 year follow-up period. Only a small proportion of COPD patients suffer continuous decline of fat-free mass <http://ow.ly/R6ioA>
Source: European Respiratory Journal
Institutions: Maastricht University Medical Centre, Ciro, Hasselt University, Brigham and Women's Hospital, Harvard University, Nebraska Medical Center, University of Nebraska Medical Center, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, GlaxoSmithKline (United States), University of Liverpool, University of Edinburgh
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: GlaxoSmithKline
OpenAlex ID: W2210675256